Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership.

Does the media refer more to OCUL or GRFS?

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 2 articles in the media. Ocular Therapeutix's average media sentiment score of 1.17 beat Grifols' score of 0.81 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is OCUL or GRFS more profitable?

Grifols has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Grifols' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-283.74%	-45.18%	-30.87%
Grifols	N/A	N/A	N/A

Do analysts rate OCUL or GRFS?

Ocular Therapeutix presently has a consensus price target of $16.38, suggesting a potential upside of 124.01%. Given Ocular Therapeutix's higher probable upside, research analysts plainly believe Ocular Therapeutix is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Which has more risk and volatility, OCUL or GRFS?

Ocular Therapeutix has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of OCUL or GRFS?

59.2% of Ocular Therapeutix shares are held by institutional investors. 3.5% of Ocular Therapeutix shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor OCUL or GRFS?

Ocular Therapeutix received 92 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 70.27% of users gave Ocular Therapeutix an outperform vote while only 56.09% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Ocular Therapeutix	Outperform Votes 442 70.27%	Underperform Votes 187 29.73%
Grifols	Outperform Votes 350 56.09%	Underperform Votes 274 43.91%

Which has better valuation & earnings, OCUL or GRFS?

Grifols has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$63.72M	18.24	-$80.74M	-$1.26	-5.80
Grifols	$7.21B	0.67	$64.20M	$1.17	6.05

Summary

Ocular Therapeutix and Grifols tied by winning 9 of the 18 factors compared between the two stocks.